Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2023 Publisher: Glaxo Wellcome UK Ltd, trading as GlaxoSmithKline UK, GSK Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK
Malarone 250 mg/100 mg film-coated tablets.
Pharmaceutical Form |
---|
Film coated tablet. Round, biconvex, pink tablets engraved ‘GX CM3’ on one side. |
Each Malarone tablet contains 250 mg atovaquone and 100 mg proguanil hydrochloride.
For the full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Atovaquone |
Atovaquone is a selective and potent inhibitor of the eukaryotic mitochondrial electron transport chain in a number of parasitic protozoa and the parasitic fungus P. jiroveci. The site of action appears to be the cytochrome bc1 complex (complex III). |
|
Proguanil |
Proguanil is an antimalarial drug and dihydrofolate reductase inhibitor. It acts like the other antifolate antimalarials by interfering with the folic-folinic acid systems and thus exerts its effect mainly at the time the nucleus is dividing. Proguanil is effective against the exoerythrocytic forms of some strains of plasmodium falciparum but it has little or no activity against the exoerythrocytic forms of p. Vivax. |
|
Proguanil and Atovaquone |
Atovaquone and proguanil interfere with two different pathways involved in the biosynthesis of pyrimidines required for nucleic acid replication. The mechanism of action of atovaquone against P. falciparum is via inhibition of mitochondrial electron transport, and collapse of mitochondrial membrane potential. One mechanism of action of proguanil, via its metabolite cycloguanil, is inhibition of dihydrofolate reductase, which disrupts deoxythymidylate synthesis. Proguanil also has antimalarial and is able to potentiate the ability of atovaquone to collapse mitochondrial membrane potential in malaria parasites. This latter mechanism may explain the synergy seen when atovaquone and proguanil are used in combination. |
List of Excipients |
---|
Core: Poloxamer 188 Coating: Hypromellose |
PVC-aluminium/paper child-resistant foil blister pack/s containing 12 tablets.
Glaxo Wellcome UK Ltd, trading as GlaxoSmithKline UK, GSK Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK
PL 10949/0258
Date of first authorisation: 21 October 1996
Date of latest renewal: 18 October 2011
Drug | Countries | |
---|---|---|
MALARONE | Austria, Australia, Canada, Estonia, Spain, Finland, France, Ireland, Israel, Japan, Lithuania, Malta, Netherlands, New Zealand, Poland, Singapore, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.